Agenus Inc (AGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
80
About the Report
About the Report
Summary
Agenus Inc (Agenus) is a clinical-stage immuno-oncology company that discovers, develops and commercializes a wide range of immunotherapeutics for the treatment of various types of cancers and infectious diseases. The company's pipeline portfolio encompasses vaccines for glioblastoma, genital herpes, and multiple cancer types; vaccine adjuvants for the treatment of shingles and malaria; and checkpoint antibodies targeted at various diseases. The company's technology portfolio includes antibody discovery platform, vaccine platforms and Heat Shock Protein (HSP) platform. The company has collaboration with several pharmaceutical companies such as GSK, Incyte, and Merck; and universities such as UC San Francisco and UW Seattle. It operates in the US and Europe. Agenus is headquartered in Lexington, Massachusetts, the US.
Agenus Inc (AGEN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Agenus Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Agenus Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Agenus Inc, Medical Devices Deals, 2012 to YTD 2018 11
Agenus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Agenus Inc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Agenus Acquires Antibody Manufacturing Facilities from XOMA 14
Agenus Enters Acquires Rights to Cell Line Development Technology from Selexis 16
Agenus Acquires Antibody Assets of Celexion 17
Venture Financing 18
PhosImmune Raises Funds through Venture Financing 18
Partnerships 19
Agenus Enters into Agreement with National Cancer Institute 19
4-Antibody And Ludwig Institute Enter Into Agreement With Recepta Biopharma For Oncology Research 20
Evotec Enters Into Agreement With 4-Antibody For Antibody Detection 21
Licensing Agreements 22
Agenus Enters into Licensing Agreement with IONTAS 22
Agenus Enters into Licensing Agreement with Diatheva 23
Merck Extends Licensing Agreement with Agenus 24
Incyte Amends Licensing Agreement with Agenus 25
Agenus Enters into Licensing Agreement with Ludwig Institute 27
Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 28
Agenus Enters Into Licensing Agreement With VaxLogic For QS-21 Stimulon 29
PhosImmune Enters into Licensing Agreement with Pure MHC 30
Equity Offering 31
Agenus to Raise Funds through Public Offering of Shares 31
Agenus Plans to Raise Funds through Public Offering of Shares 32
Celexion Sells its Stock to Agenus for USD4.3 Million 33
Agenus Plans to Raise Funds through Public Offering of Shares 34
Agenus Raises USD80 Million in Public Offering of Shares 35
Agenus Raises USD35 Million in Private Placement of Common Stock 37
Agenus Completes Public Offering Of Shares For USD 60 Million 39
Agenus Completes Private Placement Of Shares For USD 10 Million 41
Agenus Completes Private Placement Of Shares For USD 8 Million 42
Agenus Completes Private Placement Of Shares For USD 3 Million 43
Debt Offering 44
Agenus Raises USD100 Million in Private Placement of 13.5% Notes 44
Agenus Completes Private Placement Of Notes Due 2015 For USD 5 Million 46
Asset Transactions 47
XOMA Acquires Royalty Interest for Seven Assets from Agenus for USD15 Million 47
Agenus Enters into Royalty Monetization Agreement with HealthCare Royalty Partners 48
Acquisition 50
Agenus Acquires PhosImmune 50
Agenus Completes Acquisition Of 4-Antibody For USD 50 Million 51
Agenus Inc-Key Competitors 53
Agenus Inc-Key Employees 54
Agenus Inc-Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Recent Developments 56
Strategy And Business Planning 56
Oct 23, 2017: Agenus creates New Cell Therapy subsidiary named AgenTus Therapeutics 56
Financial Announcements 57
Aug 09, 2018: Agenus reports second quarter 2018 financial results and provides corporate update 57
May 07, 2018: Agenus Annnounces First Quarter 2018 Financial Results 58
Nov 07, 2017: Agenus Reports Third Quarter 2017 Financial Results and Provides Corporate Update 59
Aug 03, 2017: Agenus Reports Second Quarter 2017 Financial Results and Provides Corporate Update 60
May 04, 2017: Agenus Reports First Quarter 2017 Financial Results and Provides Corporate Update 61
Mar 09, 2017: Agenus Reports Fourth Quarter and Full Year 2016 Results 63
Corporate Communications 65
Oct 23, 2017: Bruno Lucidi Appointed Chief Executive Officer of AgenTus Therapeutics, The Cell Therapy Subsidiary of Agenus 65
Mar 30, 2017: Agenus Restructures Business to Sharpen Focus on Clinical Development of Cancer Therapies 66
Jan 30, 2017: Agenus Appoints Jean-Marie Cuillerot, M.D. Chief Medical Officer 67
Product News 68
05/17/2018: Agenus to Present Clinical Data on AGEN2034 at ASCO 2018 68
Jan 22, 2018: Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034) 69
Clinical Trials 70
Jun 04, 2018: Agenus Presents Clinical Response of AGEN2034 (anti-PD-1) at ASCO 2018 70
Jun 04, 2018: Agenus Presents Clinical Responses of AGEN1884 at ASCO 2018 71
May 17, 2018: Agenus to Present Clinical Data on AGEN-1884 at ASCO 2018 72
Apr 11, 2018: Agenus Abstracts Accepted for Presentation at the AACR 2018 Annual Meeting 73
Nov 09, 2017: Agenus To Present Data on AGEN2034 (PD-1) at SITC 2017 74
Nov 09, 2017: Agenus To Present on Lead Antibody Program AGEN1884 (CTLA-4) at SITC 2017 75
Jun 05, 2017: Agenus anti-CTLA-4 antibody shows strong safety and tolerability 76
May 22, 2017: Agenus to present safety results for anti-CTLA-4 antibody at ASCO 2017 Annual Meeting 77
Apr 05, 2017: Agenus Commences Phase 1 Trial with Neoantigen Cancer Vaccine AutoSynVax 78
Mar 07, 2017: Agenus Abstract Accepted for Presentation at the American Association for Cancer Research (AACR) 2017 Annual Meeting 79
Appendix 80
Methodology 80
About GlobalData 80
Contact Us 80
Disclaimer 80
List of Figure
List of Figures
Agenus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Agenus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Agenus Inc, Medical Devices Deals, 2012 to YTD 2018 11
List of Table
List of Tables
Agenus Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Agenus Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Agenus Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Agenus Inc, Medical Devices Deals, 2012 to YTD 2018 11
Agenus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Agenus Acquires Antibody Manufacturing Facilities from XOMA 14
Agenus Enters Acquires Rights to Cell Line Development Technology from Selexis 16
Agenus Acquires Antibody Assets of Celexion 17
PhosImmune Raises Funds through Venture Financing 18
Agenus Enters into Agreement with National Cancer Institute 19
4-Antibody And Ludwig Institute Enter Into Agreement With Recepta Biopharma For Oncology Research 20
Evotec Enters Into Agreement With 4-Antibody For Antibody Detection 21
Agenus Enters into Licensing Agreement with IONTAS 22
Agenus Enters into Licensing Agreement with Diatheva 23
Merck Extends Licensing Agreement with Agenus 24
Incyte Amends Licensing Agreement with Agenus 25
Agenus Enters into Licensing Agreement with Ludwig Institute 27
Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 28
Agenus Enters Into Licensing Agreement With VaxLogic For QS-21 Stimulon 29
PhosImmune Enters into Licensing Agreement with Pure MHC 30
Agenus to Raise Funds through Public Offering of Shares 31
Agenus Plans to Raise Funds through Public Offering of Shares 32
Celexion Sells its Stock to Agenus for USD4.3 Million 33
Agenus Plans to Raise Funds through Public Offering of Shares 34
Agenus Raises USD80 Million in Public Offering of Shares 35
Agenus Raises USD35 Million in Private Placement of Common Stock 37
Agenus Completes Public Offering Of Shares For USD 60 Million 39
Agenus Completes Private Placement Of Shares For USD 10 Million 41
Agenus Completes Private Placement Of Shares For USD 8 Million 42
Agenus Completes Private Placement Of Shares For USD 3 Million 43
Agenus Raises USD100 Million in Private Placement of 13.5% Notes 44
Agenus Completes Private Placement Of Notes Due 2015 For USD 5 Million 46
XOMA Acquires Royalty Interest for Seven Assets from Agenus for USD15 Million 47
Agenus Enters into Royalty Monetization Agreement with HealthCare Royalty Partners 48
Agenus Acquires PhosImmune 50
Agenus Completes Acquisition Of 4-Antibody For USD 50 Million 51
Agenus Inc, Key Competitors 53
Agenus Inc, Key Employees 54
Agenus Inc, Subsidiaries 55
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.